Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKDB-315 is a probiotic candidate developed by CKDBiO, specifically targeting respiratory health. As a live biotherapeutic product, it is designed to modulate the microbiome to support or improve respiratory function, likely through the gut-lung axis or immune system modulation. The candidate has completed human application studies, indicating it has progressed through initial clinical evaluation to assess its safety and efficacy in humans for respiratory indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CKDB-315.